

HT Chemiluminescent PARG Assay Kit

Chemiluminescent assay for screening
of PARG inhibitors and quantification of
PARG activity in cells and tissues.
Sufficient reagents for 96 strip wells.

Cat# 4682-096-K

HT Chemiluminescent PARG Assay Kit

Cat# 4682-096-K

Table of Contents

	Page
I. Introduction	1
II. Precautions and Limitations	1
III. Materials Supplied	1
IV. Materials/Equipment Required but not Supplied	2
V. Reagent Preparation	2
VI. PARG Inhibitor Screening Assay Protocol	4
VII. PARG Activity in Cell and Tissue Extracts	6
VIII. Data Interpretation	8
IX. References	9
X. Troubleshooting	10
XI. Related Products Available from Trevigen, Inc.	12

I. Introduction

Poly(ADP-ribose) glycohydrolase (PARG) degrades poly(ADP-ribose) (PAR) polymers synthesized by poly(ADP-ribose) polymerase (PARP1). When activated by DNA strand breaks, PARP1 uses NAD as a substrate to form ADP-ribose polymers on itself and on specific acceptor proteins such as histones, DNA polymerases, DNA ligases, p53, and Fos. These polymers are in turn rapidly degraded by PARG, a ubiquitously expressed exo- and endoglycohydrolase. Excessive activation of PARP1 leads to NAD depletion and cell death during ischemia and other conditions that generate extensive DNA damage. PARG may maintain the active state of PARP1 by continuously removing inhibitory ADP-ribose residues from PARP1.¹ The regulation of PARG activity may therefore, influence PARP-mediated cell death. First, PARG inhibition could slow the turnover of PAR and thereby limit NAD depletion. Second, PARG inhibition could prevent the removal of PAR from PARP1. Because PARP1 is inhibited by extensive poly-(ADP-ribosylation), PARG inhibitors could thereby indirectly inhibit PARP1 activity.²⁻¹⁰ Prior work has shown that the PARG inhibitor galgotannin can markedly reduce death of astrocytes after oxidative stress.¹¹ Trevigen's HT Chemiluminescent PARG Assay Kit measures the loss of biotinylated PAR from histones attached to strip wells in a 96 well format and is ideal for the screening of PARG inhibitors and for measuring the activity of PARG in cell extracts. Important features of the assay include: (1) Chemiluminescent, non-radioactive format; (2) higher throughput 96 test size; and (3) sensitivity down to 50 pg of PARG per well. Trevigen offers histone-coated 96 white strip well plates (Cat# 4678-096-P) and other components of the PARG assay separately for your convenience.

II. Precautions and Limitations

1. For Research Use Only. Not for use in diagnostic procedures.
2. The physical, chemical, and toxicological properties of the chemicals and reagents contained in the Chemiluminescent PARG Assay Kit may not yet have been fully investigated. Therefore, Trevigen recommends the use of gloves, lab coats, and eye protection while using any of these chemical reagents. Trevigen assumes no liability for damage resulting from handling or contact with these products. MSDS are available on request.

III. Materials Supplied

Cat#	Component	Amount	Storage
4680-096-01	PARG Enzyme, 1 µg/ml	100 µl	-80°C*
4680-096-02	10X PARG Buffer	8 ml	4°C
4680-096-03	DEA, 100 mM	200 µl	-80°C
4668-050-01	PARP-HSA, 10 units/µl	50 µl	-80°C
4671-096-02	20X PARP Buffer	500 µl	-80°C
4671-096-03	10X PARP Cocktail**	300 µl	-80°C
4671-096-06	10X Activated DNA	300 µl	-80°C
4678-096-P	Histone-Coated Strip Wells	96 wells	4°C
4680-096-04	Strep-HRP80	30 µl	4°C
4675-096-01	PeroxyGlow™ A	6 ml	4°C
4675-096-02	PeroxyGlow™ B	6 ml	4°C

*Components stored at -80°C are also stable at -20°C for one year in a manual defrost freezer.

**Contains biotinylated NAD.

IV. Materials/Equipment Required But Not Supplied

Reagents:

1. Inhibitors or cells/tissue to be tested.
2. PBS + 0.1% Triton® X-100
3. Distilled water
4. Phenylmethyl Sulfonyl Fluoride (PMSF) and other protease inhibitors
5. Triton® X-100 or Nonidet® P-40 for extract preparation

Disposables:

1. 1–200 µl and 100–1000 µl pipette tips
2. Eppendorf tubes

Equipment:

1. Micropipettes
2. Multichannel pipettor 1–50 µl
3. Wash bottle or microstrip wells washer (optional)
4. 96-well strip wells reader for chemiluminescence

V. Reagent Preparation

1. PBS-Triton® X-100 Wash Solution
Prepare 500 ml of 1X PBS solution containing 0.1% (v/v) Triton® X-100 in a wash bottle for washing the strip wells.
2. Strep-HRP80
Just before use, dilute Strep-HRP80 (Cat# 4680-096-04) 250-fold with 1X PARG buffer. A total of 50 µl/well of diluted Strep-HRP80 is required in the assay.
3. 1X PARP Buffer
Dilute 300 µl of the 20X PARP buffer (Cat# 4671-096-02) to 1X (1:20) with 5.7 ml of dH₂O. The 1X PARP buffer is used to dilute the PARP enzyme and to prepare the 1X PARP cocktail.
4. 1X PARP Cocktail
Prepare the 1X PARP cocktail as follows:

10X PARP cocktail (Cat# 4671-096-03)	2.5 µL/well
10X activated DNA (Cat# 4671-096-06)	2.5 µL/well
1X PARP buffer	20 µL/well
5. PARP Enzyme
The kit contains 50 µl of PARP-HSA enzyme at a concentration of 10 Units/µl. The enzyme should be diluted with 1X PARP buffer to 0.008 Units/µl just before use. For example, if you intend to ribosylate the whole plate at once, dilute 3.2 µl of the PARP enzyme with 4 ml of 1X PARP buffer and use 25 µl per well. **Note:** Diluted enzyme should be used immediately and any remainder discarded.
6. 1X PARG Buffer
Dilute 8 ml of the 10X PARG buffer (Cat# 4680-096-02) to 1X (1:10) with dH₂O. The 1X PARG buffer is used to dilute the enzyme, the Strep-HRP80, the inhibitors to be tested (if required), and to prepare cell extracts.

7. PARG Enzyme

Serially dilute the 1 µg/ml PARG standard (Cat# 4680-096-01) in microtubes with 1X PARG buffer to make at least 200 µl each dilution. The recommended final concentrations are 100 ng/ml, 30 ng/ml, 10 ng/ml, 5 ng/ml, 2.5 ng/ml, 1 ng/ml, 100 pg/ml, and 10 pg/ml. The standard curve requires 50 µl/well of each PARG dilution and each is performed in triplicate.

Note: Diluted enzyme should be used immediately and any remainder discarded. The following table describes a serial dilution protocol for PARG:

Final PARG Concentration	100 ng/ml	30 ng/ml	10 ng/ml	5 ng/ml	2.5 ng/ml	1000 pg/ml	100 pg/ml	10 pg/ml
PARG 1000 ng/ml	40 µl	200 µl	200 µl	300 µl	300 µl	200 µl	40 µl	40 µl
1X PARG Buffer	360 µl	467 µl	400 µl	300 µl	300 µl	300 µl	360 µl	360 µl

8. PARG Inhibitors

DEA (6,9-diamino-2-ethoxyacridine lactate monohydrate) is provided at 100 mM in DMSO as a control PARG inhibitor. DEA will inhibit the activity of PARG at a wide range of concentrations from 1 µM to 1 mM. In Eppendorf tubes, serially dilute the stock DEA or your PARG inhibitor(s) with 1X PARG buffer to twice their final concentrations. Transfer 100 µl of each 2X concentrated inhibitor to a series of Eppendorf tubes containing 100 µl of 20 ng/ml PARG. Mix well, incubate for 15 min at room temperature, and add to designated wells. The following table describes a serial dilution protocol for DEA:

Final DEA Concentration	2 mM	200 µM	100 µM	40 µM	20 µM	2 µM	200 nM
DEA 100 mM	10 µl	50 µl	250 µl	200 µl	250 µl	50 µl	50 µl
1X PARG Buffer	490 µl	450 µl	250 µl	300 µl	250 µl	450 µl	450 µl

9. Cell Extraction Buffer

Prepare 10 ml of the following cell extraction buffer and store at 4°C:

10X PARG buffer (Cat# 4680-096-02)	1 ml
5 M NaCl	800 µl
20% Triton X-100 or 20% NP40	450 µl
200 mM PMSF (in ethanol)	20 µl
dH ₂ O	7.73 ml

10. PeroxyGlow™ A and B Chemiluminescent Substrates

Just before use mix equal volumes of PeroxyGlow™ A and B together. PeroxyGlow™ A and B are Horseradish Peroxidase (HRP) substrates generating light that can be quantified in a suitable plate reader for luminescence. A total of 100 µl/well is required in the assay.

VI. PARG Inhibitor Screening Assay Protocol

Principal of the Assay:

Trevigen's 96-well PARG Assay Kit measures the loss of biotinylated PAR from histones attached to strip wells in a 96 well format. The histones attached to the plate wells are first poly(ADP) ribosylated by PARG using a biotinylated NAD substrate. The biotinylated PAR attached to the histones is subsequently hydrolyzed by the action of PARG in the standard or in the experimental samples. Any remaining biotinylated PAR is measured by incubation with Strep-HRP80 (which binds to the biotin) and a chemiluminescent substrate for HRP. The extent of hydrolysis is reflected by the loss in light output compared to that obtained in the absence of PARG. Inhibitors of PARG reduce the hydrolysis of the biotinylated PAR on the histones, thus minimizing the loss in light output compared to PARG alone.

When performing the PARG inhibitor protocol, the assay should be performed in triplicate and include the PARG standard curve. A general plate setup includes a negative PARP control, a negative PARG control, a PARG standard curve, serial dilutions of DEA PARG inhibitor (optional), and serial dilutions of inhibitor to be tested. A suggested plate setup is shown in Figure 3. The wells devoted to the cell extracts would be omitted in this case.

A. Ribosylation Reaction

Note: Do not premix the PARP-HSA enzyme and the 1X PARP cocktail since PARP will autoribosylate in the presence of NAD.

1. During this step PARP-HSA ribosylates the histones on the histone-coated strip wells. Remove the histone-coated strip wells from the wrapper and select the number of strip wells that you need.
2. Add 25 µl of diluted PARP enzyme (0.008 Units/µl prepared in Section V.5) to all the wells except that for the PARP negative control (well H12, Fig.3). Substitute 25 µl of 1X PARP Buffer in this well.
3. Distribute 25 µl of 1X PARP cocktail (prepared as described in Section V.4) into each well using a multichannel pipettor.

4. The final reaction volume is 50 µl:	<u>Volume</u>	<u>Order of Addition</u>
	Diluted PARP-HSA enzyme (0.008 Unit/µl)	25 µl 1
	1X PARP cocktail	25 µl 2

5. Incubate the strip wells at room temperature for 60 min.
6. Wash strip wells 4 times with 1X PBS + 0.1% Triton® X-100 (200 µl/well). Ensure that all the liquid is removed following each wash by tapping strip wells onto paper towels.

B. Hydrolysis Reaction

1. Prepare negative control and standard curve samples:
 - a. *PARG Standard Curve*: Serially dilute the 1 µg/ml PARG standard in microtubes with 1X PARG buffer as described in Section V.7 above. Add 50 µl of each PARG dilution to triplicate wells (columns 1 to 3, rows B to H, Fig. 3).
 - b. *PARG Negative control*: Include a negative control without PARG to provide the 100% reference light output (columns 1 to 3, row A, Fig. 3).
 - c. *PARG Negative control*: This control measures the nonspecific binding of Streptavidin-HRP80 to the histones in the strip wells (well H12).
2. Prepare inhibitor samples:
 - a. In 1.5 ml tubes, prepare twice-concentrated serial dilutions of the control DEA PARG inhibitor and/or your inhibitor in 1X PARG buffer as described in Section V.8 above. Include one tube containing 1X PARG assay buffer without inhibitor. This tube provides the 100% activity reference point.
 - b. Transfer 100 µl of each 2X concentrated inhibitor to a series of Eppendorf tubes containing 100 µl of 20 ng/ml PARG. Mix well, incubate for 15 min at room temperature, and add to designated wells. **Note**: Always premix your inhibitor with PARG before adding to the strip wells.
 - c. Each 1.5 ml tube will contain sufficient inhibitor and PARG for triplicate wells at 50 µl per well:

Component	Volume	Order of Addition
20 ng/ml PARG	100 µl	1
Diluted test inhibitor, DEA, or 1X PARG buffer	100 µl	2
Total volume	200 µl	

Note: The final concentration of PARG will be 10 ng/ml and the inhibitors will be at their final 1X concentrations.

3. Add the PARG and PARG negative controls, PARG standard curve dilutions and inhibitor/PARG mixtures to triplicate ribosylated strip wells at 50 µl/well (see Fig. 3).
 4. Incubate the strip wells at room temperature for 60 min.
- ### C. Detection
1. Wash strip wells 4 times with 1X PBS + 0.1% Triton® X-100 (200 µl/well). Ensure that all the liquid is removed following each wash by tapping strip wells onto paper towels.
 2. Add 50 µl per well of diluted Strep-HRP80 (prepared in Section V.2). Incubate at room temperature for 60 min.
 3. Wash strip wells 4 times with 1X PBS + 0.1% Triton® X-100 (200 µl/well). Ensure that all the liquid is removed following each wash by tapping strip wells onto paper towels.

4. Just before use mix equal volumes of PeroxyGlow™ A and B together and add 100 µl per well. Immediately take chemiluminescent readings.

VII. PARG Activity in Cell and Tissue Extracts

When performing the PARG activity protocol, the assay should be performed in triplicate. A general plate setup includes a negative PARG control, a negative PARG control, a standard curve, and serial dilutions of extract to be tested. A general plate setup is shown in Figure 3 for testing of four extracts. The wells devoted to the PARG inhibitors would be omitted in this case.

A. Processing Cells

Suspension cells: Centrifuge 2×10^6 to 1×10^7 suspension cells at 400 x g for 10 min at 4°C. Discard the supernatant. Suspend the cell pellet in 1 ml of ice-cold 1X PBS and transfer to a prechilled 1.5 ml microtube. Centrifuge at 10,000 x g for 10 sec at 4°C. Discard the supernatant and proceed to step VII.C.

Adherent cells: Wash 2×10^6 to 1×10^7 adherent cells with 1X PBS. Adherent cells may be harvested by scraping in 5 ml of ice-cold 1X PBS or by gentle trypsinization. Transfer to a prechilled 15 ml tube. Centrifuge at 400 x g for 10 min at 4°C and discard the supernatant. Suspend the cell pellet in 1 ml of ice-cold 1X PBS and transfer to a prechilled 1.5 ml microtube. Centrifuge at 10,000 x g for 10 sec at 4°C. Discard the supernatant and proceed to step VII.C.

B. Processing Tissue

1. Remove tissue and place in cold PBS in a 50 ml conical tube. Repeatedly wash the tissue with cold PBS to remove blood clots and other debris.
2. Transfer the tissue to a Petri dish on ice and mince the tissue to small pieces with surgical scissors.
3. Transfer the tissue pieces to a clean stainless steel sieve. Place the sieve with the tissue pieces in a Petri dish which contains about 20 ml of cold 1X PBS.
4. Create a single cell suspension of the tissue as follows: Using a pestle or a round bottom tube, grind the tissue pieces thoroughly until the bulk of the tissue passes through the sieve.
5. Transfer the cell suspension to a 50 ml conical tube. Fill with cold PBS and mix by inverting the tube several times. Let the tube stand on ice for 1 min to allow large aggregates of tissue to settle out of solution.
6. Carefully transfer the supernatant containing the single cell suspension to a clean 50 ml conical centrifuge tube. Determine the number of cells at this point. Centrifuge at 400 x g for 10 min at 4°C. Discard the supernatant. Suspend the cell pellet in 1 ml of ice-cold 1X PBS and transfer to a prechilled 1.5 ml microtube. Centrifuge at 10,000 x g for 12 sec at 4°C. Discard the supernatant and proceed to step VII.C.

C. Preparation of Extracts

1. Suspend the cell pellet in 5–10 pellet volumes of cold cell extraction buffer from Step V.9. Incubate the cell suspensions on ice, with periodic vortexing, for 30 min.
2. Microcentrifuge the disrupted cell suspension at 10,000 x g for 10 min at 4°C to remove insoluble material. Recover the supernatant to a fresh tube prechilled on ice. Occasionally, the pellet may float and can easily be removed with a pipet tip.
3. Determine the protein concentration of the cleared cell lysate. Use at least 10 µg of protein per well in the assay. **Note:** 1X PARG buffer contains 0.1 mg/ml BSA.
4. Snap-freeze the cleared cell extract in small aliquots and store at -80°C. Avoid repeated freezing and thawing of the extract.

D. Ribosylation Reaction

Note: Do not premix the cell extract and the 1X PARP cocktail since PARP will autoribosylate in the presence of NAD.

1. Perform the ribosylation reaction as described in Section VI A.

E. Hydrolysis Reaction

1. Each sample will be in 3 wells. Distribute 50 µl of your sample into each of the designated 3 wells. **Note:** serial dilutions of your sample in 1X PARG assay buffer may be required to optimize PARG activity determination.
2. Controls:
 - i. **PARG Standard Curve:** Serially dilute the 1 µg/ml PARG standard in microtubes with 1X PARG buffer such that the concentration is 100 ng/ml, 30 ng/ml, 10 ng/ml, 3 ng/ml, 1 ng/ml, 300 pg/ml, and 100 pg/ml. Add 50 µl of each standard to triplicate wells (columns 1 to 3, rows B to H, Fig. 3).
 - ii. **PARG Negative control:** Include a negative control without PARG to provide the 100% reference light output (columns 1 to 3, row A, Fig. 3).
 - iii. **PARP Negative control:** This control measures the nonspecific binding of Streptavidin-HRP80 to the histones in the strip wells (well H12, Fig. 3).
3. Incubate the strip wells at room temperature for 60 min.

F. Detection

1. Follow Section VI. C in the PARG Inhibitor Screening Assay Protocol.

VIII. Data Interpretation

Typical PARG activity curves and inhibition curves for the PARG inhibitor DEA are graphically represented in Figures 1 and 2, respectively. The activity of PARG is expressed as the percent cleavage of PAR and is calculated as follows:

Let A = Light output in the absence of PARG
B = Light output in the presence of PARG

$$\% \text{ Cleavage of PAR} = \frac{(A - B)}{A} \times 100$$

Plot the percent cleavage of PAR versus log [PARG, pg/ml]. Determine the PARG activity in your cell extract from the standard curve. Express the results as µg of PARG/mg protein.




Figure 1. Graphical representation of PARG Activity curve

The inhibition of PARG caused by your inhibitor will be reflected as an *increase* in the observed light output readings relative to that caused by 10 ng/ml PARG in the absence of inhibitor.

Let C = Light output in the presence of PARG inhibitor
D = Light output in the absence of PARG inhibitor

$$\% \text{ Inhibition of PARG} = \frac{(C - D)}{C} \times 100$$

IC₅₀ = the concentration of inhibitor that reduces the activity of PARG by 50%




Figure 2. Graphical representation of DEA Inhibition curve in which 10 ng/ml PARG was used per determination. A composite of three separate experiments is shown.

IX. References

1. Koh DW, Dawson VL, Dawson TM. 2005. The road to survival goes through PARG. *Cell Cycle*. 4:397-399.
2. Oei SL, Keil C, Ziegler M. 2005. Poly(ADP-ribosylation) and genomic stability. *Biochem Cell Biol*. 83:263-269.
3. Cuzzocrea S, Wang ZQ. 2005. Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion. *Pharmacol Res*. 52:100-108.
4. Bonicalzi ME, Haince JF, Droit A, Poirier GG. 2005. Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? *Cell Mol Life Sci*. 62:739-750.
5. Patel NS, Cortes U, Di Poala R, Mazzon E, Mota-Filipe H, Cuzzocrea S, Wang ZQ, Thiernemann C. 2005. Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury. *J Am Soc Nephrol*. 16:712-719.
6. Patel CN, Koh DW, Jacobson MK, Oliveira MA. 2005. Identification of three critical acidic residues of poly(ADP-ribose) glycohydrolase involved in catalysis: determining the PARG catalytic domain. *Biochem J*. 388:493-500.
7. Falsig J, Christiansen SH, Feuerhahn S, Burkle A, Oei SL, Keil C, Leist M. 2004. Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools. *Eur J Pharmacol*. 497:7-16.

8. Cortes U, Tong WM, Coyle DL, Meyer-Ficca ML, Meyer RG, Petrilli V, Hecceg Z, Jacobson EL, Jacobson MK, Wang ZQ. 2004. Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. *Mol Cell Biol*. 24:7163-7178.
9. Hanai S, Kanai M, Ohashi S, Okamoto K, Yamada M, Takahashi H, Miwa M. 2004. Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in *Drosophila melanogaster*. *Proc Natl Acad Sci U S A*. 101:82-86.
10. Lu XC, Massuda E, Lin Q, Li W, Li JH, Zhang J. 2003. Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat. *Brain Res*. 18:99-103.
11. Ying W, and Swanson RA. 2000. The poly(ADP-ribose) glycohydrolase inhibitor gallotannin blocks oxidative astrocyte death. *Neuroreport*. 11:1385-1388.

X. Troubleshooting

PROBLEM	CAUSE	SOLUTION
High light output in wells with PARG Inhibitor at all inhibitor dilutions.	PARG inhibitor is extremely potent.	Increase the serial dilutions of your inhibitor.
High light output in wells with PARG alone in PARG inhibitor studies.	PARG enzyme was not added to the wells.	Add 100 μ L of 20 ng/ml PARG to each 1.5 ml tube as described in Section VI.B.2.
Low light output in wells containing cell extracts.	PARG expression in cells too high.	Increase the serial dilutions of your cell extracts in 1X PARG Assay Buffer.
High light output in PARG standard curve in wells with high concentrations of PARG	High background due to poor washing	Increase the number of washing steps.

	1	2	3	4	5	6	7	8	9	10	11	12
A	100 ng/ml PARG	100 ng/ml PARG	100 ng/ml PARG	1000 µM DEA + 10 ng/ml PARG	1000 µM DEA + 10 ng/ml PARG	1000 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #1 20 µg Protein	Cell/Tissue Extract #1 20 µg Protein	Cell/Tissue Extract #1 20 µg Protein	Cell/Tissue Extract #1 20 µg Protein	Cell/Tissue Extract #3 5 µg Protein	No PARG
B	30 ng/ml PARG	30 ng/ml PARG	30 ng/ml PARG	100 µM DEA + 10 ng/ml PARG	100 µM DEA + 10 ng/ml PARG	100 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #1 10 µg Protein	Cell/Tissue Extract #1 10 µg Protein	Cell/Tissue Extract #1 10 µg Protein	Cell/Tissue Extract #3 5 µg Protein	Cell/Tissue Extract #4 20 µg Protein	No PARG
C	10 ng/ml PARG	10 ng/ml PARG	10 ng/ml PARG	50 µM DEA + 10 ng/ml PARG	50 µM DEA + 10 ng/ml PARG	50 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #1 5 µg Protein	Cell/Tissue Extract #1 5 µg Protein	Cell/Tissue Extract #1 5 µg Protein	Cell/Tissue Extract #4 20 µg Protein	Cell/Tissue Extract #4 20 µg Protein	No PARG
D	5 ng/ml PARG	5 ng/ml PARG	5 ng/ml PARG	20 µM DEA + 10 ng/ml PARG	20 µM DEA + 10 ng/ml PARG	20 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #2 20 µg Protein	Cell/Tissue Extract #2 20 µg Protein	Cell/Tissue Extract #2 20 µg Protein	Cell/Tissue Extract #4 10 µg Protein	Cell/Tissue Extract #4 10 µg Protein	Cell/Tissue Extract #4 10 µg Protein
E	2.5 ng/ml PARG	2.5 ng/ml PARG	2.5 ng/ml PARG	10 µM DEA + 10 ng/ml PARG	10 µM DEA + 10 ng/ml PARG	10 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #2 10 µg Protein	Cell/Tissue Extract #2 10 µg Protein	Cell/Tissue Extract #2 10 µg Protein	Cell/Tissue Extract #4 5 µg Protein	Cell/Tissue Extract #4 5 µg Protein	No PARG
F	1 ng/ml PARG	1 ng/ml PARG	1 ng/ml PARG	1 µM DEA + 10 ng/ml PARG	1 µM DEA + 10 ng/ml PARG	1 µM DEA + 10 ng/ml PARG	Cell/Tissue Extract #2 5 µg Protein	Cell/Tissue Extract #2 5 µg Protein	Cell/Tissue Extract #2 5 µg Protein	Cell/Tissue Extract #4 5 µg Protein	Cell/Tissue Extract #5 20 µg Protein	No PARG
G	100 pg/ml PARG	100 pg/ml PARG	100 pg/ml PARG	100 nM DEA + 10 ng/ml PARG	100 nM DEA + 10 ng/ml PARG	100 nM DEA + 10 ng/ml PARG	Cell/Tissue Extract #3 20 µg Protein	Cell/Tissue Extract #3 20 µg Protein	Cell/Tissue Extract #3 20 µg Protein	Cell/Tissue Extract #5 20 µg Protein	Cell/Tissue Extract #5 20 µg Protein	No PARG
H	10 pg/ml PARG	10 pg/ml PARG	10 pg/ml PARG	No DEA + 10 ng/ml PARG	No DEA + 10 ng/ml PARG	No DEA + 10 ng/ml PARG	Cell/Tissue Extract #3 10 µg Protein	Cell/Tissue Extract #3 10 µg Protein	Cell/Tissue Extract #3 10 µg Protein	Cell/Tissue Extract #5 10 µg Protein	Cell/Tissue Extract #5 10 µg Protein	Cell/Tissue Extract #5 10 µg Protein

Figure 3. Suggested layout for a PARG standard curve, PARG inhibitor serial dilutions, and for assay of PARG in cell extracts. Note that the histones on the plate must first be poly(ADP) ribosylated following Section VI.A.

XI. Related Products Available From Trevigen

Kits:

Catalog #	Description	Size
4683-096-K	HT Colorimetric PARG Assay Kit	96 samples
4520-096-K	HT PARG In Vivo Pharmacodynamic Assay II	96 tests
4690-096-K	HT F Homogeneous PARG Inhibition Assay Kit	96 tests
4671-096-K	HT Universal Color PARG Assay Kit/w Histone Reagents	96 tests
4675-096-K	HT Universal Chemiluminescent PARG Assay Kit/w Histone Reagent	96 tests
4676-096-K	HT Universal Chemiluminescent PARG Assay Kit/w Histone Coated Strip Wells	96 tests
4677-096-K	HT Universal Colorimetric PARG Assay Kit/w Histone Coated Strip Wells	96 tests
4684-096-K	HT Colorimetric PARG/Apoptosis Assay	96 tests
4685-096-K	HT Chemiluminescent PARG/Apoptosis Assay	96 tests

Inhibitors and Antibodies:

Catalog #	Description	Size
4667-50-11	Benzamide PARG inhibitor (8 mM)	100 µl
4667-50-03	3-Aminobenzamide PARG inhibitor (200 mM)	100 µl
4667-50-10	6(5H)-Phenanthridinone PARG inhibitor (160 µM)	100 µl
4667-50-9	4-Amino-1,8-naphthalimide PARG inhibitor (800 µM)	100 µl
4335-AMC-050	PAR Monoclonal Antibody Affinity Purified	50 µl
4335-MC-100	Anti-PAR Monoclonal Antibody	100 µl
4336-APC-050	PAR Polyclonal Antibody Affinity Purified	50 µl
4336-BPC-100	Anti-PAR Polyclonal Antibody (rabbit)	100 µl
4338-MC-50	Anti-PARG Monoclonal Antibody (clone C2-10)	50 µg
2305-PC-100	Anti-Cleaved Caspase 3 Polyclonal	100 µl

Poly(ADP)-ribose:

Catalog #	Description	Size
4336-100-01	Poly(ADP) Ribose (PAR) Polymer	100 µl

PARG:

Catalog #	Description	Size
4680-096-01	PARG	100 µl

The product accompanying this document is intended for research use only and is not intended for diagnostic purposes or for use in humans.

Trevigen, Inc.

8405 Helgerman Ct. Gaithersburg, MD 20877

Tel: 1-800-873-8443 • 301-216-2800

Fax: 301-560-4973

e-mail: info@trevigen.com

www.trevigen.com



Please Recycle